Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 15 versus CLORPRES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 15 versus CLORPRES.
ALDORIL 15 vs CLORPRES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
CLORPRES is a combination of clonidine (alpha-2 adrenergic agonist that reduces sympathetic outflow) and chlorthalidone (thiazide diuretic that inhibits sodium reabsorption in distal tubules).
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
One tablet (clonidine 0.1 mg/chlorthalidone 15 mg) orally once or twice daily; maximum 0.6 mg clonidine/90 mg chlorthalidone daily.
None Documented
None Documented
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Terminal elimination half-life is 4-6 hours; may be prolonged in renal impairment, requiring dose adjustment.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Renal excretion accounts for approximately 50% of elimination, with 30% as unchanged drug and 20% as metabolites; biliary/fecal elimination accounts for about 10%.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination